Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, today announced that it will present clinical safety data from its First in Human healthy volunteer study, and data from a gene expression study of patients with advanced fibrosis at the American Association for the Study of Liver Disease (AASLD) 2020 Annual Meeting
| CAMBRIDGE, Mass., Nov. 10, 2020 /PRNewswire/ -- Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, today announced that it will present clinical safety data from its First in Human healthy volunteer study, and data from a gene expression study of patients with advanced fibrosis at the American Association for the Study of Liver Disease (AASLD) 2020 Annual Meeting taking place virtually on Nov. 13-16.
“We are developing our novel technology to better understanding progression of diseases, such as NASH, to improve disease detection and patient treatment,” said Wendy Winckler, Ph.D., Chief Scientific Officer at Glympse Bio. “The data we are presenting at AALSD will demonstrate that our synthetic biosensors, which measure the activity of proteases associated with NASH, are safe and well-tolerated in healthy volunteers. Based on this data we’re looking forward to advancing the program into pivotal studies in NASH.” Details are as follows: Poster Number: 1516 About Glympse Bio Media Contact
SOURCE Glympse Bio |
View original content to download multimedia:
